First Quadrant’s Acorda Therapeutics ACOR Stock Holding History

First Quadrant’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-111	Closed	-$177K	–	762
2019 Q1	$177K	Buy	111 +41	+59%	+$73.9K	0.01%	513
2018 Q4	$131K	Sell	70 -53	-43%	-$115K	0.01%	606
2018 Q3	$290K	Sell	123 -110	-47%	-$341K	0.01%	581
2018 Q2	$804K	Buy	233 +229	+5,725%	+$701K	0.02%	433
2018 Q1	$10K	Buy	+4	New	+$12K	﹤0.01%	801

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

First Quadrant's ACOR Position: Q2 2019 in Review

First Quadrant sold out of Acorda Therapeutics (ACOR) in Q2 2019, closing a stake of 111 shares — an estimated $177K sold.

First Quadrant first reported a position in ACOR in Q1 2018 and held it in 5 quarters. The position peaked at $804K in Q2 2018. 163 funds tracked by Wall St. Rank hold ACOR as of Q2 2019.

First Quadrant reported no remaining Acorda Therapeutics position as of Q2 2019 after selling out during the quarter.
First Quadrant sold 111 Acorda Therapeutics shares in Q2 2019, an estimated $177K.
First Quadrant first reported a position in Acorda Therapeutics in Q1 2018 and held it in 5 quarters.
First Quadrant's Acorda Therapeutics position peaked at $804K in Q2 2018.
163 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2019.

Based on First Quadrant's 13F filing for Q2 2019, filed 24 Jul 2019.